Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe licensed weight loss injections available in the UK, tirzepatide (Mounjaro) and semaglutide (Wegovy), are prescription-only medicines that can be dispensed by a registered pharmacy, including GPhC-registered online pharmacies, after a clinical assessment confirms they are suitable for you. No pharmacist, online or on the high street, can hand one over without a valid prescription. That matters because the clinical trial evidence behind these medicines is built on supervised use — the results come from patients who were assessed, monitored and supported, not from unsupervised self-treatment. If you are exploring this route, understanding what the evidence actually shows, and what a legitimate dispensing process looks like, is the right place to start.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The strongest evidence for injectable weight loss medicines in the UK comes from two large, rigorously controlled programmes. SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity to tirzepatide or placebo over 72 weeks. Participants at the highest dose saw an average body-weight reduction of around 20–21%. The STEP 1 trial did the same for semaglutide 2.4mg and reported roughly 15% average loss over 68 weeks. Those figures are not marketing estimates. They come from controlled conditions in which participants received regular clinical reviews, dose adjustments and lifestyle support alongside the injections.
That context is not a footnote. It is the mechanism. Both medicines work by reducing appetite and slowing gastric emptying, but titration (starting low and increasing gradually) is how tolerability is managed. The starter dose of tirzepatide at 2.5mg exists to let your system adjust before the dose rises; the prescriber decides the pace. A pharmacy that dispenses without that ongoing relationship is not replicating the trial conditions that produced those headline results. You can explore the broader landscape of weight loss injections licensed in the UK to see how the two medicines compare in practice.
Because Mounjaro and Wegovy are prescription-only, the dispensing pathway has fixed legal steps. First, a prescriber assesses you, reviewing your BMI, weight-related conditions, current medicines, and medical history. For tirzepatide, the licensed threshold is a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. The prescriber decides; BMI alone does not guarantee approval.
Once a prescription is issued, a GPhC-registered pharmacy can dispense. Online pharmacies follow the same legal framework as a high-street chemist and must hold a GPhC premises registration, which you can check on the GPhC public register. At nume, every consultation is read by a GPhC-registered Independent Prescriber on the day it is submitted, a real clinician, not automated decision software. Orders placed before 12pm on a working day are dispatched the same day once clinically approved, arriving free via tracked DPD the next working day. If you tend to order around payday or at the start of a new month, the 12pm cut-off is worth noting in your calendar.
Injection technique matters too. Tirzepatide and semaglutide are both given subcutaneously (under the skin of the abdomen, thigh or upper arm) and the site should be rotated each week. Alcohol swabs for cleaning the injection site are a practical accessory worth having to hand. Your Patient Information Leaflet covers the full technique; your prescriber can answer questions about it directly.
The side-effect profile of GLP-1 and dual GIP/GLP-1 medicines is well characterised. The most common effects are gastrointestinal: nausea, loose stools, constipation, reflux, or burping, especially after starting treatment or moving to a higher dose. For most people these settle within a couple of weeks. Fatigue, mild headache and injection-site reactions also appear in trial data. The NHS medicines page for tirzepatide lists these in plain English and is worth bookmarking.
Some symptoms need prompt medical attention. Severe stomach pain that radiates to the back, with or without vomiting, requires urgent review; in January 2026 the MHRA issued a Drug Safety Update confirming acute pancreatitis as an infrequent but potentially serious effect of GLP-1 medicines. Signs of a serious allergic reaction, gallbladder symptoms, or significant dehydration from prolonged vomiting or diarrhoea are also reasons to call NHS 111 or seek urgent care rather than waiting for your next prescription review. Suspected side effects (and any concerns about counterfeit or unlicensed products) can be reported at yellowcard.mhra.gov.uk.
These medicines are not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. They are not licensed for under-18s. If you take an oral contraceptive, tirzepatide can reduce how well it is absorbed: a non-oral method should be used alongside it for the first four weeks of treatment and for four weeks after each dose increase. Your prescriber will go through this with you at consultation. For a fuller look at what is involved in starting treatment, if you are trying to decide between options, our full list of weight loss injections can help you understand what is currently available before you read the guide to weight loss injections, which covers the process from eligibility to aftercare.
NHS access to these medicines is real but restricted. NICE recommends tirzepatide (TA1026) for adults with a BMI of 35 or above and at least one weight-related comorbidity, and the phased NHS rollout through GP practices is under way, though participation by individual practices is optional and availability varies by area. Semaglutide (Wegovy) is available on the NHS but typically only through specialist weight management services, which carry their own waiting times. For people who do not yet meet NHS thresholds, or who prefer not to wait, a private prescription through a GPhC-registered online pharmacy is the legal alternative. The route that does not require a GP referral is precisely this: a direct consultation with an independent prescriber.
On cost: private treatment is priced per pen and varies by dose and provider. Since Eli Lilly's UK list-price increase in September 2025, typical private market prices have ranged roughly £149–£375 per month depending on the dose and the provider, as widely reported. What that price should always include is the consultation, prescription, dispensing and clinical follow-up; prices that strip those elements out to look cheaper on a comparison site are not like-for-like. If you are comparing providers and want to understand how a specific medicine works before committing, our weight loss injection overview is a useful starting point alongside the cost breakdown for weight loss injections from a chemist, which explains this in detail. Choosing a registered pharmacy you can verify is a more meaningful test than finding the lowest headline figure.
Ready to find out whether you are clinically suitable? Check your eligibility with our prescribers, the consultation is free, and you will have a clinical answer the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.